Fig. 4: Heatmap of selected CNA and SNV oncogenic drivers in CTCs, matched tumour biopsies and cfDNA at combined dabrafenib plus trametinib therapy failure, according to their clinical relevance and/or presence in ≥5 patients. | British Journal of Cancer

Fig. 4: Heatmap of selected CNA and SNV oncogenic drivers in CTCs, matched tumour biopsies and cfDNA at combined dabrafenib plus trametinib therapy failure, according to their clinical relevance and/or presence in ≥5 patients.

From: Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer

Fig. 4

Altered genes are attributed to pathways. The four main pathways are sorted from the most altered to the least altered. The number of altered genes per pathway is shown in parentheses. CNA driver function (activating or loss of function) is mentioned in the “Role” column. Frequencies of CNAs and driver SNVs in the 57 samples (53 CTCs and 4 tumour biopsies) and the 64 samples (53 CTCs, 4 tumour biopsies and 7 cfDNA), respectively, are provided. Red and blue colours represent gains and losses, respectively.

Back to article page